Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 281-286 , April 2008

Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins

  • Nathan E. Basken

      Affiliations

    • Division of Nuclear Pharmacy, Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN 47907, USA
    • ,
  • Carla J. Mathias

      Affiliations

    • Division of Nuclear Pharmacy, Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN 47907, USA
    • ,
  • Alexander E. Lipka

      Affiliations

    • Department of Statistics, Purdue University, West Lafayette, IN 47907, USA
    • ,
  • Mark A. Green

      Affiliations

    • Division of Nuclear Pharmacy, Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN 47907, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 765 494 1445; fax: +1 765 496 3367.

Received 20 July 2007 ,Revised 11 October 2007 ,Accepted 17 November 2007.

References 

  1. Winters ME. In: Basic clinical pharmacokinetics. Philadelphia (Pa): Lippincott Williams & Willkins; 1994;p. 9–17
  2. Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem. 2002;9:1463–1481
  3. Peters T. In: All about albumin. San Diego (Calif): Academic Press Inc; 1996;p. 102–127
  4. In:  Lenter C editors. Geigy Scientific Tables. CIBA-GEIGY; 1984;p. 140–141
  5. Carter DC, Ho JX. Structure of serum albumin. In: Advances in protein chemistry. San Diego (Calif): Academic Press; 1994;p. 176–189
  6. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 2005;353:38–52
  7. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol. 1975;11:824–832
  8. Panjehshahin MR, Yates MS, Bowmer CJ. A comparison of drug binding sites on mammalian albumins. Biochem Pharmacol. 1992;44(5):873–879
  9. Robertson A, Karp W, Broderson R. Comparison of the binding characteristics of serum albumins from various animal species. Dev Pharmacol Ther. 1990;15:106–111
  10. Kosa T, Maruyama T, Otagiri M. Species differences of serum albumins: I. Drug binding sites. Pharm Res. 1997;14(11):1607–1612
  11. Green MA, Klippenstein DL, Tennison JR. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET. J Nucl Med. 1988;29:1549–1557
  12. Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Kinetics of copper-PTSM in isolated hearts: a novel tracer for measuring blood flow with positron emission tomography. J Nucl Med. 1989;30:1843–1847
  13. Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Assessment of regional myocardial and renal blood flow using copper-PTSM and positron emission tomography. Circulation. 1990;82:990–997
  14. Herrero P, Markham J, Weinheimer CJ, Anderson CJ, Welch MJ, Green MA. Quantification of regional myocardial perfusion with generator-produced 62Cu-PTSM and positron emission tomography. Circulation. 1993;87:173–183
  15. Green MA, Mathias CJ, Welch MJ, McGuire A, Perry D, Fernandez-Rubio F. [62Cu]-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato) copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med. 1990;31:1989–1996
  16. Herrero P, Hartman JJ, Green MA, Anderson CJ, Welch MJ, Markham J. Assessment of regional myocardial perfusion with generator-produced 62Cu-PTSM and PET in human subjects. J Nucl Med. 1996;37:1294–1300
  17. Beanlands RS, Muzik O, Mintun MA, Mangner T, Lee K, Petry N. The kinetics of copper-62-PTSM in the normal human heart. J Nucl Med. 1992;33:684–690
  18. Melon PG, Brihaye C, Degueldre C, Guillaume M, Czichosz R, Rigo P. Myocardial kinetics of K-38 in humans and comparison with Cu-62-PTSM. J Nucl Med. 1994;35:1116–1122
  19. Beanlands RS, Muzik O, Hutchins GD, Woulfe ER, Schwaiger M. Heterogeneity of regional nitrogen-13-labeled ammonia tracer distribution in the normal human heart: comparison with rubidium-82 and copper-62-labeled PTSM. J Nucl Cardiol. 1994;1:225–235
  20. Wallhaus TR, Lacy J, Whang J, Green MA, Nickles RJ, Stone CK. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM. J Nucl Med. 1998;39:1958–1964
  21. Wallhaus TR, Lacy J, Stewart R, Bianco J, Green MA, Nayak N. Copper-62-pyruvaldehyde bis(N-4-methylthiosemicarbazone) PET imaging in the detection of coronary artery disease in humans. J Nucl Cardiol. 2001;8:67–74
  22. http://www.proportionaltech.com/cuets.htm.
  23. Green MA, Mathias CJ, Willis L, Handa R, Miller M, Hutchins G. Evaluation of Cu-ETS as a PET tracer of regional renal perfusion. J Labelled Compd Radiopharm. 2005;48:S164
  24. Green MA, Mathias CJ, Willis LR, Handa RK, Miller MA, Hutchins GD. Evaluation of 62Cu-ETS as a PET tracer of renal perfusion in a model of acute focal renal Injury. J Nucl Med. 2006;47(Suppl 1):146P
  25. Green MA, Mathias CJ, Willis LR, Handa RK, Lacy JL, Miller MA. Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion. Nucl Med Biol. 2007;34:247–255
  26. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med. 2001;45:183–188
  27. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N-4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655–661
  28. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N-4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499–504
  29. Lewis JS, Herrero P, Sharp TL, Engelbach JA, Fujibayashi Y, Laforest R. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N-4-methylthiosemicarbazone). J Nucl Med. 2002;43:1557–1569
  30. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent Cu-64(II)-diacetyl-bis(N-4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–998
  31. Serganova I, Humm J, Ling C, Blasberg R. Tumor hypoxia imaging. [Editorial Material] Clin Cancer Res. 2006;12(18):5260–5264
  32. Blower PJ, Castle TC, Cowley AR, Dilworth JR, Donnelly PS, Labisbal E. Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans. 2003;23:4416–4425
  33. Petering HG, Buskirk HH, Underwood GE. The anti-tumor activity of 2-keto-3 ethoxybutyraldehyde bis(thiosemicarbazone) and related compounds. Cancer Res. 1964;24:367–372
  34. John E, Green MA. Structure-activity relationships for metal-labeled blood flow tracers: comparison of ketoaldehyde bis(thiosemicarbazonato)copper(II) derivatives. J Med Chem. 1990;33:1764–1770
  35. Casella G, Berger R. In: Statistical inference. Pacific Grove (Calif): Duxbury; 2002;p. 240–245
  36. SAS, version 9.1.3. Cary (NC): SAS Institute Inc; 2002-2003;
  37. Mathias CJ, Bergmann SR, Green MA. Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin. J Nucl Med. 1995;36:1451–1455
  38. Yuan H, Antholine WE, Subczynski WK, Green MA. Release of CuPTSM from human serum albumin after addition of fatty acids. J Inorg Biochem. 1996;61:251–259
  39. Boukhout BA, Van Asten-Noordijk JJL, Stok W. Porcine IgG. Isolation of two IgG-subclasses and anti-IgG class- and subclass-specific antibodies. Mol Immunol. 1986;23:675–683
  40. Minkel DT, Saryan LA, Petering DH. Structure-function correlations in the reaction of bis(thiosemicarbazone) copper(II) complexes with Ehrlich ascites tumor cells. Cancer Res. 1978;38:124–129
  41. Petering DH. Carcinostatic copper complexes. In:  Sigel H editors. Metal ions in biological systems. New York: Marcel Dekker; 1980;p. 197–229
  42. Winkelmann DA, Bermke Y, Petering DH. Comparative properties of the antineoplastic agent 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazone) copper(II) and related chelates: linear free energy relationships. Bioinorg Chem. 1974;3:261–277
  43. Baerga ID, Maickel RP, Green MA. Subcellular distribution of tissue radiocopper following intravenous administration of 67Cu-labeled Cu-PTSM. Nucl Med Biol. 1992;19:697–701

☆ This work was supported by a research grant from the Purdue Research Foundation, and R01-CA092403. The production of Cu-64 at Washington University School of Medicine is supported by the NCI grant R24 CA86307.

PII: S0969-8051(07)00301-0

doi: 10.1016/j.nucmedbio.2007.11.009

Nuclear Medicine and Biology
Volume 35, Issue 3 , Pages 281-286 , April 2008

Article Tools

* Image Usage & Resolution